Drug Database
FI

filgrastim (Lupifil / filgrastim, Lupin)

✓ Approved

Lupin Limited · CSF3R · Recombinant Proteins

What is filgrastim?

filgrastim is a recombinant proteins developed by Lupin Limited. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

Brand NamesLupifil, filgrastim, Lupin
CompanyLupin Limited
Drug ClassRecombinant Proteins
Molecular TargetCSF3R
RouteInjectable (Others), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Lupin Limited

Mechanism of Action

Molecular Targets

filgrastim acts on 1 molecular target:

CSF3Rcolony stimulating factor 3 receptor (CD114, GCSFR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

filgrastim is developed for 3 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Blood and lymphatic system disordersNeutropenia✓ Approved
Blood and lymphatic system disordersBone marrow disorder✓ Approved
Surgical and medical proceduresHaematopoietic stem cell mobilisationPreclinical

Related Research Articles

PubMedFrontiers in pediatrics2026-07-06

Granulocyte colony-stimulating factor-induced hypersensitivity reaction with leukocytosis in a pediatric germ cell tumor patient: a case report.

Tan Yuhui Y, Wei Chaoyong C, Xiao Wenyan W, Fu Yilan Y et al.

Chemotherapy-induced bone marrow suppression significantly increases the risk of febrile neutropenia (FN) in cancer patients. Granulocyte colony-stimulating factor (G-CSF) is a cornerstone therapy for FN prophylaxis and treatment that promotes myeloid progenitor cell proliferation and differentiation, thereby reducing the duration of neutropenia. While G-CSF is generally well tolerated and has a favorable safety profile, rare but life-threatening adverse events may occur. We present the case of a 14-year-old female with a germ cell tumor who developed a systemic hypersensitivity reaction following prophylactic administration of efbemalenograstim alfa-vuxw (20 mg/dose) after her third chemotherapy cycle. Notably, the patient had previously tolerated two full doses of efbemalenograstim alfa-vuxw and one full dose of short-acting G-CSF (filgrastim biosimilar 5 μg/kg) without any adverse events during the first two chemotherapy cycles. Within two hours post-injection, she exhibited severe hypotension (74/52 mmHg), hypoxemia (SpO₂ 81%), and marked leukocytosis (55.32 → 104.25 × 10⁹/L within 24 h). Emergency intervention with epinephrine and dexamethasone resolved the symptoms. Peripheral blood analysis revealed eosinophilia (0.16 × 10⁹/L), suggesting drug sensitization. During the fourth chemotherapy cycle, subcutaneous recombinant human G-CSF (rhG-CSF, filgrastim biosimilar; 5 μg/kg) was administered, but the patient experienced a nearly identical reaction within 30 min (BP 53/29 mmHg, SpO₂ 97%). The temporal correlation and clinical consistency confirmed a G-CSF-induced systemic hypersensitivity reaction. To our knowledge, this represents the first documented pediatric case of recurrent systemic hypersensitivity reactions induced by sequential administration of different G-CSF formulations following chemotherapy. Notably, long-acting G-CSF (efbemalenograstim alfa-vuxw) was associated with both hypersensitivity and pronounced leukocytosis. Our findings highlight the following: 1. Hypersensitivity to G-CSF, although rare, requires heightened clinical vigilance; 2. The Substitution of G-CSF products may not preclude recurrent reactions; 3. The safety profile and optimal dosing of efbemalenograstim alfa-vuxw in pediatric populations warrant further validation in controlled trials.

PMID 42403385
Read full article →
PubMedEcancermedicalscience2026-07-02

Establishment of the first bone marrow transplant program in francophone sub-Saharan Africa: clinical case and future perspectives.

Niang Elhadji Daouda ED, Fall Seynabou S, Toure Sokhna Aissatou SA, Camara Marieme Lolita ML et al.

Haematopoietic stem cell transplantation (HSCT) offers curative potential for several malignant and non-malignant hematologic disorders. Despite its proven efficacy, access to HSCT in sub-Saharan Africa remains limited, especially in francophone countries, due to the lack of infrastructure, cryobiology facilities and trained personnel. Senegal recently launched a national initiative to establish its first HSCT program. We report the first autologous HSCT performed in Senegal in February 2025 at Dalal Jamm University Hospital, in a 51-year-old man diagnosed with high-risk IgA-lambda multiple myeloma (ISS stage III, del17p). Mobilisation was achieved using filgrastim (10 µg/kg/day for 7 days). A total of 2.8 × 10⁶ CD34⁺ cells/kg were collected by apheresis and stored at 4°C for 24 hours without cryopreservation. Conditioning consisted of high-dose intravenous melphalan (200 mg/m2) followed by reinfusion of the graft on day 0. Hematologic recovery occurred by day +10, with transient grade 3 anemia and grade 4 thrombocytopenia requiring transfusion support. The main complications were manageable febrile neutropenia and mild gastrointestinal and renal toxicities. The patient was discharged on day +17, remained infection-free and achieved complete hematologic and biochemical remission at five months post-transplant. Consolidation therapy with bortezomib-thalidomide-dexamethasone and lenalidomide maintenance was subsequently administered. This first non-cryopreserved autologous HSCT in Senegal demonstrates the feasibility, safety and cost-effectiveness of transplantation under resource-limited conditions. Establishing local cryopreservation and molecular diagnostic capabilities will be essential to enable tandem and allogeneic HSCT, ensuring sustainability and regional self-sufficiency in advanced hematologic care.

PMID 42389559
Read full article →
PubMedIn vivo (Athens, Greece)2026-07-01

Rescue of Suprasellar Metastasis of EGFR-mutant NSCLC by Daily Osimertinib Re-escalation With Filgrastim Support.

Saito Shoichiro S, Matsuda Shuichi S, Nakamura Masato M, Takahashi Rina R et al.

Managing central nervous system (CNS) metastases of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer can be challenging if dose-limiting toxicities prevent adequate drug exposure. We report the case of a 70-year-old woman with a suprasellar metastasis abutting the optic chiasm for whom radiotherapy was contraindicated. Although treatment with 80 mg osimertinib once daily was begun, recurrent grade 3 neutropenia required a dose reduction to 40 mg every other day. During alternate-day dosing, the suprasellar lesion progressed despite continued control of extracranial disease, threatening the patient's vision. To enhance exposure of the CNS to osimertinib, its dosage was escalated to 40 mg once daily supported by granulocyte colony-stimulating factor (filgrastim). This strategy successfully led to tumor regression and maintained disease control without unmanageable toxicity. This case suggests that dose reduction can weaken the effect of osimertinib on the CNS and that maintaining dose intensity using granulocyte colony-stimulating factor support is a viable and effective strategy for controlling CNS lesions in eloquent areas when local therapy is contraindicated.

PMID 42379747
Read full article →
PubMedCancer treatment and research communications2026-06-03

Pegfilgrastim versus filgrastim for chemo-mobilized stem cell collection in multiple myeloma: A retrospective real-world study.

Zhang Yan-Lin YL, Qin Xin-Yi XY, Cao Chun C, Luo Zhi-Ming ZM et al.

Autologous stem cell transplantation (ASCT) is a standard treatment for newly diagnosed multiple myeloma (MM). Achieving sufficient stem cell yield via effective mobilization promotes successful hematological reconstitution. However, clinical evidence regarding the comparative outcomes of pegfilgrastim (PEG) versus filgrastim (FIL) remains controversial, lacking regimen-specific comparisons. To evaluate the efficacy, safety, efficiency, and costs of PEG versus FIL in MM patients, and compare the impact of cyclophosphamide-based chemo-mobilization on these outcomes. This single-center retrospective study included 102 MM patients (PEG: n = 49; FIL: n = 53). Primary endpoints were CD34⁺ cell yield, mobilization success, duration, and time to engraftment. Statistical analyses included propensity score matching (PSM), overlap weighting (OW), and subgroup analysis. In the overall cohort, PEG and FIL showed equivalent median CD34⁺ yields (3.90 vs. 4.99 × 10⁶/kg, P = 0.096), mobilization success rates, and total hospitalization costs (P = 0.53). FIL yielded a higher total mononuclear cell count (P < 0.001). Subgroup analysis revealed PEG reduced mobilization duration (10 vs. 15 days, P < 0.001) and sessions in chemo-mobilization. PSM showed comparable yields and engraftment. To address PSM sample attrition and balance covariates, OW was utilized, further confirming that PEG significantly shortened overall duration (P = 0.04) and reduced sessions (P = 0.02). Both regimens exhibited similar engraftment kinetics and safety. Both PEG and FIL demonstrate equivalent efficacy for stem cell mobilization in MM. PEG offers superior efficiency by shortening duration and reducing sessions without increasing the total economic burden.

PMID 42229263
Read full article →
PubMedZhongguo shi yan xue ye xue za zhi2026-06-02

[Efficacy and Safety of Mecapegfilgrastim versus rhG-CSF for Peripheral Blood Stem Cell Mobilization in Healthy Donors: A Comparative Study].

Tang Liu L, Chen Yan Y, Zuo Xiu-Qin XQ, Xing Hong-Yun HY et al.

To compare the efficacy, safety, and pharmacoeconomic differences between Mecapeg-filgrastim and recombinant human granulocyte colony-stimulating factor （rhG-CSF） in mobilizing peripheral blood stem cells （PBSCs） from healthy donors. A total of 100 healthy donors who underwent PBSC mobilization at our center between January 2022 and June 2025 were included and assigned to the Mecapegfilgrastim group or the rhG-CSF group. Successful mobilization was defined as CD34+cells ≥2×106/kg, and optimal mobilization as ≥5×106/kg. The mobilization efficacy, adverse events, and medical costs between the two groups were compared. Outcomes of the corresponding recipients were evaluated, including the dose of infused cells, the time to hematopoietic recovery, and the incidence of acute graft-versus-host disease（aGVHD）. The mobilization success rate was 100% in both groups. The optimal mobilization rate （98.0% vs. 80.0%, P=0.004） and median number of mobilized CD34+ cells ［7.84（4.86-20.86） vs. 5.85（2.99-15.20）×106/kg, P<0.001］ in the mecapeg-filgrastim group were significantly higher than that in the rhG-CSF group, while the number of mononuclear cells was lower ［10.13（5.38-24.80） vs. 12.16（4.99-28.38） × 108/kg, P=0.049］. The engraftment rates of the two groups of recipients （88% vs. 90%） and aGVHD incidence rates （52.3% vs. 48.9%） showed no significant differences（P>0.05）. However, compared with the rhG-CSF group, the Mecapegfilgrastim group showed significantly shorter neutrophil （14 vs. 16 days） and platelet （13 vs. 22 days） engraftment time （both P<0.001）. The incidence and spectrum of adverse events were comparable between the two groups, with no statistically significant difference（32.0% vs.30.0%, P>0.05）. Additionally, compared with the rhG-CSF group, the Mecapegfilgrastim group had a shorter donor hospitalization length ［2（2-3） vs. 6（6-7）days］ and lower mobilization costs（both P<0.001）. In healthy donor PBSC mobilization, Mecapegfilgrastim is non-inferior to rhG-CSF, offers superior promotion of hematopoietic recovery in recipients, and provides significant advantages in reducing hospital stay and medical costs with a comparable safety profile. Mecapegfilgrastim thus represents a more cost-effective mobilization strategy.

PMID 42227452
Read full article →
PubMedCureus2026-06-01

Rare Invasive Fusarium Sinusitis in a Transiently Immunosuppressed Patient.

Archibald Vincent L VL, Meenrajan Senthil R SR, Schain Denise D, Tishena Anastasia A et al.

A Florida cattle rancher undergoing treatment for lumbar osteomyelitis presented with severe neutropenia and febrile episodes after being discharged on a seven-week course of intravenous (IV) vancomycin and cefepime. Upon admission, antibiotics were changed, and micafungin and filgrastim were added. Several days later, he had a normalizing absolute neutrophil count (ANC) and improving fevers with an overall good clinical appearance. Discharge seemed near, but he continued to complain of nasal congestion and mild oromaxillary pain. In caution, a CT maxillofacial scan and ENT evaluation were performed that revealed extensive nasal septal necrosis with cultures growing Fusarium suttonianum, prompting treatment with IV liposomal amphotericin, IV voriconazole, and oral terbinafine. Due to reported resistance to FDA-approved antifungals, compassionate use medications were explored. Clinically, he continued to look well and reported minimal symptoms despite the severity of necrosis. The patient responded well to triple antifungal therapy inpatient and continued therapy at home until antifungals were paused due to amphotericin-induced acute kidney injury. He had completed 38/42 days of planned treatment at this point, so the decision was made to hold antifungals (including potential compassionate use medications) until his upcoming ENT debridement. This ENT evaluation then confirmed no residual disease. Continuation of the antifungal regimen and additional compassionate use medications were not pursued, and the patient continued to do well. This case teaches to take the potential hematological complications of many antibiotics seriously and raises further teaching points to consider on the risks and management of rare, rapidly progressing invasive infections such as Fusarium.

PMID 42220831
Read full article →

+2276 more articles available with a free account

Sign up free to view all articles →

Ask about filgrastim